12:00 AM
Sep 28, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pollinex Quattro Ragweed: Development ongoing

Allergy said that it was increasingly optimistic that FDA would lift a clinical hold on the company's clinical program for Pollinex Quattro allergy vaccines, citing a recent vote by an FDA panel in favor of approval of Cervarix, an HPV vaccine from GlaxoSmithKline plc (London, U.K., LSE:GSK; NYSE: GSK) that uses the same adjuvant (see BioCentury, Sept. 14). Allergy said it is "optimistic that U.S. approval of Cervarix will result and will mark the...

Read the full 370 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >